Navigation Links
AHF Seeks White House Clarification After Press Room Flap Over CDC's HIV Numbers
Date:12/11/2007

LOS ANGELES, Dec. 11 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) is seeking clarification from the White House regarding a press briefing late last week during which Deputy Press Secretary Dana Perino had a curt exchange with reporter Les Kingsolving over questions he tried to pose regarding the Centers for Disease Control (CDC) and its latest US HIV data. Kingsolving, from the ultra-conservative Media Research Center, started to ask about the CDC's latest HIV statistics and infection rates among men who have sex with men (MSM), but Perino refused to acknowledge the questions and moved on to another reporter. The CDC has not yet publicly released these new US numbers, which are widely expected to show a dramatic 35% to 50% increase in HIV rates. According to CDC officials, the reason for the delay is that the data is currently under "peer review" at a scientific journal and will not be released to the public until early in 2008, a move that has angered and frustrated AIDS activists nationwide.

"There are just too many unanswered questions from this White House Press Room exchange on a crucial domestic AIDS issue for us not to ask the White House and Ms. Perino for clarification," said Michael Weinstein, President of AIDS Healthcare Foundation. "It is widely understood that Kingsolving has a separate agenda, but AHF would like to know if the White House truly believes that it was, 'inappropriate ... to bring up those questions in the briefing room,' as Ms. Perino remarked about Kingsolving's line of HIV/AIDS questioning, or was she merely responding to that particular messenger? More important, what is the White House response to this pending CDC announcement of a much higher domestic HIV rate? And does the White House support the fact that the CDC seems to be stonewalling on the release of these numbers? From both a public health perspective and as the Administration works to finish preparing its 2008 budget, the timely release of such
'/>"/>

SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
6. The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh
7. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
8. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
9. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
10. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
11. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...tCall/ -- BioForm Medical,Inc. (Nasdaq: BFRM ) t...Polidocanol, conducted in Germany by BioForm Medic...H (Kreussler), successfully met the study primary,...a New Drug Application,(NDA) process., In the piv...safety of,Aethoxysklerol compared to Sodium Tetrad...
(Date:9/4/2008)...ented at ESC Congress-, PHILADELPHIA, Sept. 4 /PR...y, the GISSI Heart Failure (GISSI-HF) study, showe...uced all cause mortality and hospital,admissions f... heart,failure. These findings are published in th...presented at the European Cardiovascular Society (...
(Date:9/4/2008)...outhern Research Institute,today announced that th...,the organization to participate in the newly-fund...work (MLPCN). The MLPCN -- a collaborative,researc...ogram which is,designed to benefit human health, b...d validate future targets for drug discovery., So...
(Date:9/4/2008)...e/ -- Axentis Pharma AG has,initiated a clinical p...ty,of a new therapeutic formulation for the treatm...is patients. The new formulation allows an,establi... the site of,infection. The forthcoming trial will...f the new drug. Initial results are expected in su...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Microchip Biotechnologies Inc Collaborating With Stanford University on Developing a Front End Microfluidic Based Sample Preparation System for Pyro 3591 1Microchip Biotechnologies Inc Collaborating With Stanford University on Developing a Front End Microfluidic Based Sample Preparation System for Pyro 3591 2Vermillion Receives Award From the Society of Gynecologic Oncologists 1441 1Vermillion Receives Award From the Society of Gynecologic Oncologists 1441 2Vermillion Receives Award From the Society of Gynecologic Oncologists 1441 3Vermillion Receives Award From the Society of Gynecologic Oncologists 1441 4Natures helpers 3A Using microorganisms to remove TCE from water 12998 1Natures helpers 3A Using microorganisms to remove TCE from water 12998 2Natures helpers 3A Using microorganisms to remove TCE from water 12998 3The Female Health Company Receives USAID DELIVER PROJECT Order for 6 1 Million Units 12995 1The Female Health Company Receives USAID DELIVER PROJECT Order for 6 1 Million Units 12995 2
... and Regulatory Development of Oral,Anti-Inflammat...ire-FirstCall/ -- Celgene,Corporation announced it... anti-inflammatory candidates across a broad range...an oral TNF,antagonist and anti-inflammatory agent...llent side effect profile in a placebo,controlled ...
...2007 /PRNewswire/ -- NanoBio,Corporation, a biopha...the treatment and prevention of serious infections...ase 1 clinical study of,NB-002, the company,s drug...or the topical treatment of onychomycosis. , The P...7 and,involved 20 subjects who received twice-dail...
Other Medicine Technology:Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 2Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 3Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases 4NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis 2NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis 3
(Date:9/8/2008)...aser scalpels, arthroscopic,surgery, genomic resea...rinary medicine is quickly expanding into new high...e benefit; it,s improving medicine for,people, too... care for their pets to,treat diseases like diabet... according to the American Veterinary Medical Asso...
(Date:9/8/2008)...zine examines Iraq and Afghanistan veterans, strug..., Washington, DC (PRWEB) S...by veterans of the Iraq and Afghanistan wars about... addiction disorders are featured in the current i...ublication of the National Council for Community B...
(Date:9/7/2008)...f older patients successfully treated for colorect...le to detect any recurrence of cancer. The study, ... , a peer-reviewed journal of the American Cancer ...monitoring of colorectal cancer survivors could af...y curative surgery for colorectal cancer have an i...
(Date:9/7/2008)... appear to lower a man,s PSA level, the blood biom...her a man is at risk of prostate cancer. , But t.... 8 in the journal Cancer , caution that men shou... prostate cancer just yet. , "We showed that me...rin and other non-steroidal anti-inflammatory drug...
Breaking Medicine News(10 mins):Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:Helping Veterans in Our Communities 2Health News:Helping Veterans in Our Communities 3Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Common painkillers lower levels of prostate cancer biomarker 2
...unique public-private partnership in healthcare, t...ll ensure medical care for the poor that will be p... The Sarva Swasthya Mission Trust is the brainchi...as roped in major investors to provide funds. He h...
...ia become a "near-epidemic" in the Dooars region o...re than 20,000 persons in the past two and a half ...y.// Nirmal Das, an MLA from Alipurduar constitue...at 48 deaths had been reported from Alipurduar sub...
...n biotech major Biocon Ltd has roped in Bayer Heal...ugen in the Chinese market, the company //said in ...h firm plans to launch Insugen in China by 2007-08...stration trials and seeking the regulatory approva...
...aldomero Olivera said that the ruthless fish-eatin... back pain.// He is planning to present his findi...snails, with their striking patterns and elegant s...tching shells on display and for sale at the annua...
Other Medicine News:Health News:Bayer to Market Biocon Insulin in China 2
The new Nellcor N-45 Handheld Pulse Oximeter is compatible with our complete line of OxiMax Pulse Oximetry Sensors, so clinicians have the convenience of Nellcors most advanced sensor technology in a
...or's most popular handheld oximeter has been conve... and is now compatible with the entire line of inn...ehead Sensor and SoftCare Nonadhesive Sensors. The...also incorporates Nellcor's latest advanced signal...
...ellcor N395 Pulse Oximeter with Oxismart XL Advanc...ion conditions, cutting through nonspecific noise ...rate values. , ,The N395 monitor is also equi...ugh in clinician-programmable alarm sensitivity fo...
...e cornerstone of the revolutionary OxiMax® Pul...r combines Nellcor's best-in-class pulse oximetry ... motion-tolerant OxiMax N-595 Pulse Oximeter is eq...ing technology, which enables it to withstand the ...
Medicine Products: